Cargando…

Esophageal cancer responsive to the combination of immune cell therapy and low-dose nivolumab: two case reports

BACKGROUND: Blocking the programmed death 1 pathway by immune checkpoint inhibitors induces dramatic antitumor activity in patients with malignant tumors. However, the clinical response to immune checkpoint inhibitors remains limited owing to the patients’ immunological status, such as the number of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takimoto, Rishu, Kamigaki, Takashi, Gotoda, Takuji, Takahashi, Toshimi, Okada, Sachiko, Ibe, Hiroshi, Oguma, Eri, Goto, Shigenori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8028114/ https://www.ncbi.nlm.nih.gov/pubmed/33827668 http://dx.doi.org/10.1186/s13256-020-02634-z

Ejemplares similares

Significant clinical response of advanced colorectal cancer to combination therapy involving capecitabine and adoptive cell transfer therapy: a case report
por: Li, Shuchun, et al.
Publicado: (2019)

Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer
por: Miura, Miyabi, et al.
Publicado: (2020)

Zoledronate-pulsed dendritic cell-based anticancer vaccines
por: Kamigaki, Takashi, et al.
Publicado: (2013)

Nivolumab in combination with radiotherapy for metastatic esophageal neuroendocrine carcinoma after esophagectomy: a case report
por: Takagi, Kuniyasu, et al.
Publicado: (2021)

Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial
por: Hirooka, Yoshiki, et al.
Publicado: (2017)

Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3
por: Chin, Keisho, et al.
Publicado: (2022)

Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab–ipilimumab in metastatic gastric and esophageal cancer
por: Derks, Sarah, et al.
Publicado: (2022)

Low-dose nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2022)

Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)
por: Takahashi, Masanobu, et al.
Publicado: (2020)

Severe Esophagitis and Gastritis from Nivolumab Therapy
por: Boike, Justin, et al.
Publicado: (2017)

Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
por: Okada, Morihito, et al.
Publicado: (2022)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer
por: Kato, Ken, et al.
Publicado: (2020)

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
por: Danno, Tetsuya, et al.
Publicado: (2021)

A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma
por: Kijima, Yu, et al.
Publicado: (2021)

Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma
por: Liu, Shixian, et al.
Publicado: (2022)

Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma
por: Hamai, Yoichi, et al.
Publicado: (2023)

Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma
por: Sun, Dantong, et al.
Publicado: (2020)

The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer
por: Takegawa, Naoki, et al.
Publicado: (2023)

Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report
por: Takimoto Sato, Michiko, et al.
Publicado: (2020)

Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2018)

Complete Remission of Vocal Cord Cancer Treated With Low-Dose Ipilimumab Plus Nivolumab Combined With Interleukin-2 and Hyperthermia
por: Kleef, Ralf, et al.
Publicado: (2021)

Nivolumab‐induced sialadenitis
por: Takahashi, Saeko, et al.
Publicado: (2018)

Myasthenic crisis and polymyositis induced by one dose of nivolumab
por: Kimura, Toshihiro, et al.
Publicado: (2016)

Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report
por: Cho, Hye Jung, et al.
Publicado: (2021)

Nivolumab-Induced Colitis in a Patient With Esophageal Adenocarcinoma: A Case Report
por: Vlachos, Iakovos, et al.
Publicado: (2023)

Endoscopic submucosal dissection by use of a modified dental floss clip method for recurrent tumor in the cecum
por: Ikehara, Hisatomo, et al.
Publicado: (2017)

Non-Curative Resection: Should Clinicians Consider Providing Additional Surgery for All Patients?
por: Hatta, Waku, et al.
Publicado: (2020)

Importance of Metronidazole in Vonoprazan-based Helicobacter pylori Treatment in Japan
por: Suzuki, Sho, et al.
Publicado: (2023)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
por: Lai, Gillianne G.Y., et al.
Publicado: (2022)

Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe
por: Yamazaki, Daisuke, et al.
Publicado: (2013)

Safety evaluation of fixed‐dose nivolumab in patients with gastric cancer
por: Iikura, Yusuke, et al.
Publicado: (2022)

Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma
por: Sakakibara-Konishi, Jun, et al.
Publicado: (2020)

A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy
por: Horisberger, Alice, et al.
Publicado: (2018)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Identifying high-risk individuals for gastric cancer surveillance from western and eastern perspectives: Lessons to learn and possibility to develop an integrated approach for daily practice
por: Quach, Duc Trong, et al.
Publicado: (2019)

A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

Evidence‐based rationale for low dose nivolumab in critically ill patients with sepsis‐induced immunosuppression
por: van den Haak, Demy A. C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_66e2spp8niehtjc2sr3re5rrji